| Assay ID | Title | Year | Journal | Article |
|---|
| AID104577 | Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID352591 | Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
| Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID281485 | Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID232750 | Selectivity index is the ratio between CC50 for MT-4 cells and IC50 against HIV-1 infection | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. |
| AID198238 | Inhibitory activity against HIV-1 reverse transcriptase | 1996 | Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
| Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. |
| AID1125802 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from cytopathic effect | 2014 | European journal of medicinal chemistry, Apr-22, Volume: 77 | QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. |
| AID200003 | Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade | 2001 | Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
| Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. |
| AID106965 | Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 | 1989 | Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
| A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID352588 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
| Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID106964 | Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID89169 | Inhibitory activity against HIV-1 (HTLV-IIIRF strain) replication in MT-4 cells | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID198389 | Inhibitory effect on HIV-1 reverse transcriptase activity using poly(rA)-oligo(dT) template primer | 1989 | Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
| A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID83577 | Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells (HIV-1 HTLV-IIIB strain) by 50% was determined on 4th day after virus infection. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID46620 | Concentration which reduces the cell viability by 50% (CEM-SS / MT-4) | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID53666 | Inhibitory activity against DNA polymerase-alpha derived from peripheral blood mononuclear cells | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID83263 | Concentration of compound required to reduce the viability of mock-infected HIV-2 (LAV-2ROD)/MT-4 cells by 50% | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID89165 | Cytotoxic concentration of compound required to incorporate [5-3H]-Urd into RNA of mock infected peripheral blood lymphocytes in HIV-1 (HTLV-IIIB)by 50% | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID80887 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB strain) and determined on 4th day after virus infection. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID45854 | Cytotoxic concentration for inhibition of HTLB-IIIB replication in CEM cells. | 1997 | Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
| Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. |
| AID89166 | Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID198565 | Inhibition of HIV-1 reverse transcriptase (RT) | 1995 | Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
| A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. |
| AID83100 | Concentration of compound required to reduce the viability of mock-infected PBL(peripheral blood lymphocytes) cells. by 50% | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID155468 | The compound was tested for toxicity in peripheral blood mononuclear cells. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID104274 | Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
| Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. |
| AID89308 | Inhibitory activity against HIV-2(LAV-2EHO strain) replication in MT-4 cells | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID199671 | Inhibition of HIV-1 reverse transcriptase from peripheral blood mononuclear cells. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID235889 | Ratio of effective concentration to that of cytotoxic concentration against HIV-1 induced cytopathogenicity in MT-4 cells | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
| 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] ( |
| AID104938 | Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% | 1995 | Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
| Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. |
| AID105892 | Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line MT-4 IIIB | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID80886 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID248354 | Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB) | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
| Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA. |
| AID83108 | Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID199980 | Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) | 2002 | Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
| Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. |
| AID89309 | Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID287164 | Antiviral activity against HIV2 ROD in MT4 cells after 4 days by MTT method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
| Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID199103 | Inhibitory concentration required to inhibit the HIV-1 reverse transcriptase activity | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia |
| AID217434 | Antiviral activity against Vero cells, infected with HSV-1. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID106609 | Cytotoxic concentration that reduces the MT-4 cell viability by 50% | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. |
| AID46175 | Effective concentration for inhibition of HTLB-IIIB replication in CEM cells. | 1997 | Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
| Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. |
| AID287166 | Selectivity index, ratio of CC50 for MT4 cells to IC50 for HIV1 3B | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
| Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID105124 | Compound was evaluated for effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 | 1995 | Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
| Design and synthesis of novel inhibitors of HIV-1 reverse transcriptase. |
| AID81255 | Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
| 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] ( |
| AID666972 | Cytotoxicity against human MT4 cells after 5 days by MTT assay | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. |
| AID104452 | Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral infection of MT-4 cells | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. |
| AID235634 | Selectivity index is the ratio of CC50/EC50 | 1989 | Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
| A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID235878 | Ratio of EC50/CC50 | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID217744 | The compound was tested for toxicity in Vero cells. | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID104448 | Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. |
| AID104450 | Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells; NA denotes not active | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. |
| AID83101 | Concentration required inhibit HIV-1 (HTLV-IIIb strain) replication in PBL(peripheral blood lymphocytes) cells. | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID157572 | Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-2(strain ROD-2). | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID46198 | Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells. | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. |
| AID352590 | Cytotoxicity against human MT4 cells by MTT assay | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
| Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID352589 | Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
| Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID666971 | Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. |
| AID287163 | Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
| Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID198390 | Inhibitory effect on HIV-1 reverse transcriptase activity using poly(rC)-oligo(dG) template primer | 1989 | Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
| A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID46619 | Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in human T-4 lymphoblastoid cell line CEM-SS/LAI | 1997 | Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
| Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID287165 | Cytotoxicity against MT4 cells after 4 days by MTT method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
| Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID281486 | Cytotoxicity against MT4 cells after 4 days by MTT method | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID106599 | Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% | 1989 | Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
| A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID157570 | Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-1(strain LAV). | 1991 | Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
| Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. |
| AID46199 | Inhibitory effect against HIV-2 replication in CEM cells. | 1995 | Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
| Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. |
| AID89168 | Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in peripheral blood lymphocytes | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID235683 | Selectivity Index measured as the ratio of EC50 to that of CC50 values. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID106589 | Concentration required to reduce human MT-4 cell viability by 50%. | 1992 | Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
| 3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] ( |
| AID105513 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. | 1995 | Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
| Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. |
| AID231665 | CC50/EC50 ratio expressed as selectivity index(SI) | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID225321 | Concentration required to reduce viability of mock-infected MT-4 cells | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
| Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. |
| AID666973 | Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3 | 2012 | European journal of medicinal chemistry, Aug, Volume: 54 | Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. |
| AID235557 | Ratio of the EC50 against HIV-1 infected MT-4 cells and CC50 against mock infected MT-4 cells. | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
| Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. |
| AID106587 | Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. |
| AID89167 | Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells | 1991 | Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
| Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID80888 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIRF strain) and determined on 4th day after virus infection. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID106588 | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID83118 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 (LAV-2ROD strain) and determined on 4th day after virus infection. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID83117 | Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 ((LAV-2EHO strain) and determined on 4th day after virus infection. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
| A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). |
| AID281489 | Selectivity index, CC50 for MT4 cells/IC50 for HIV1 3B | 2007 | Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
| Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. |
| AID83264 | Concentration required inhibit HIV-2 (LAV-2ROD)replication in MT-4 cells. | 1992 | Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
| Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. |
| AID235678 | Selectivity Index measured as ratio of CC50 to that of EC50. | 1997 | Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
| Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 1995 | Nature structural biology, Apr, Volume: 2, Issue:4
| High resolution structures of HIV-1 RT from four RT-inhibitor complexes. |
| AID1795396 | HIV-1 RT Assay from Article 10.1021/jm0309856: \\Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
| Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |